- •Epstein–Barr virus is considered a risk factor for the development of multiple sclerosis.
- •EBNA IgG titer increases during the inflammatory phase of the MS and as the disease duration increases.
- •EBNA IgG was significantly associated with disease activity regarding relapse severity and lesion location and could be a potential biomarker for predicting disease exacerbation.
- •However, more extensive studies are needed to evaluate the cut-off level of antibody titer for practical use.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- Herpesvirus trigger accelerates neuroinflammation in a nonhuman primate model of multiple sclerosis.Proc. Natl. Acad. Sci. USA. 2018; 115: 11292-11297https://doi.org/10.1073/pnas.1811974115
- Antibodies to Epstein–Barr virus and MRI disease activity in multiple sclerosis.Mult. Scler. 2014; 20: 1833-1840https://doi.org/10.1177/1352458514533843
- Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis.Ann. Neurol. 2006; 59: 499-503https://doi.org/10.1002/ana.20820
- Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.Proc. Natl. Acad. Sci. USA. 2004; 101 (SupplSuppl): 14599-14606https://doi.org/10.1073/pnas.0404874101
- Longitudinal analysis reveals high prevalence of Epstein–Barr virus associated with multiple sclerosis.Science (1979). 2022; 375: 296-301https://doi.org/10.1126/science.abj8222
- Attenuated immune control of Epstein–Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15.Eur. J. Immunol. 2021; 51: 64-75https://doi.org/10.1002/eji.202048655
- Persistence of Epstein–Barr virus in self-reactive memory B cells.J. Virol. 2012; 86: 12330-12340https://doi.org/10.1128/JVI.01699-12
- A functional and structural basis for TCR cross-reactivity in multiple sclerosis.Nat. Immunol. 2002; 3: 940-943https://doi.org/10.1038/ni835
- An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis.PLoS One. 2010; 5https://doi.org/10.1371/journal.pone.0012496
- Environmental risk factors for multiple sclerosis. Part I: the role of infection.Ann. Neurol. 2007; 61: 288-299https://doi.org/10.1002/ana.21117
- Group the NEBVW, Epstein–Barr virus in the multiple sclerosis brain: a controversial issue report on a focused workshop held in the centre for brain research of the medical university of Vienna, Austria.Brain. 2011; 134: 2772-2786https://doi.org/10.1093/brain/awr197
- B-cell therapy for multiple sclerosis: entering an era.Ann. Neurol. 2018; 83: 13-26https://doi.org/10.1002/ana.25119
- Immunology of multiple sclerosis.Ann. Rev. Immunol. 2005; 23: 683-747https://doi.org/10.1146/annurev.immunol.23.021704.115707
- Transcriptional profile and Epstein–Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis.J. Neuroinflamm. 2018; 15: 18https://doi.org/10.1186/s12974-017-1049-5
- A gradient of neuronal loss and meningeal inflammation in multiple sclerosis.Ann. Neurol. 2010; 68: 477-493https://doi.org/10.1002/ana.22230
- Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells.J. Immunol. 2006; 176: 3498-3506https://doi.org/10.4049/jimmunol.176.6.3498
- Association between clinical disease activity and Epstein–Barr virus reactivation in MS.Neurology. 2000; 55: 178-184https://doi.org/10.1212/wnl.55.2.178
- Environmental risk factors for multiple sclerosis. Part II: noninfectious factors.Ann. Neurol. 2007; 61: 504-513https://doi.org/10.1002/ana.21141
- Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria.Acta Neurol. Scand. 2004; 109: 385-389https://doi.org/10.1111/j.1600-0404.2004.00246.x
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.Lancet Neurol. 2018; 17: 162-173https://doi.org/10.1016/S1474-4422(17)30470-2
- Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology. 1983; 33: 1444-1452https://doi.org/10.1212/wnl.33.11.1444
- The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. national MS society clinical outcomes assessment task force.Mult. Scler. 1999; 5: 244-250https://doi.org/10.1177/135245859900500409
- The Turkish validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) battery.BMC Neurol. 2017; 17: 208https://doi.org/10.1186/s12883-017-0993-0
- Epstein–Barr virus and disease activity in multiple sclerosis.J. Neurol. Neurosurg. Psychiatry. 2005; 76: 1377-1381https://doi.org/10.1136/jnnp.2004.048504
- Prognostic factors in multiple sclerosis.Int. Rev. Neurobiol. 2007; 79: 423-447https://doi.org/10.1016/S0074-7742(07)79019-0
- Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.Neurology. 2009; 73: 32-38https://doi.org/10.1212/WNL.0b013e3181aa29fe
- Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS.Neurol.(R) Neuroimmunol. Neuroinflamm. 2016; 3: e190https://doi.org/10.1212/NXI.0000000000000190
- Early MRI predictors of prognosis in multiple sclerosis.J. Neurol. 2019; 266: 3171-3173https://doi.org/10.1007/s00415-019-09589-2
- Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?.Ann. Neurol. 2006; 59: 597-605https://doi.org/10.1002/ana.20832